BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types ...

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious ...

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types ; MAINZ, Germany, ...

Bristol Myers Squibb will pay BioNTech $1.5 billion upfront and up to $7.6 billion in potential milestone payments through 2028. Disclaimer: This is an AI-generated summary of a press release ...

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced that the companies have entered into an agreement for the global co-development and co ...